GLP-1s, touted as a miracle drug by many, are slowly disappearing from Americans' insurance plans. Bloomberg workplace reporter Taylor Nicole Rogers explains why companies are saying “no thanks” to one of the hottest classes of pharmaceuticals on the market. And then, what would you do if you were in $30,000 of credit card debt? Debt Heads podcast co-host Jamie Feldman gives her negative balance a casual shrug, and makes the argument that you should too.